CD34 and myelodysplastic syndrome: Despite the use of next generation sequencing (NGS) technologies, for example, a systematic immunity screening approach of BM biopsies (BMB) of MDS patients analyzing the landscape of immune cells and CD34+ blasts is necessary to understand host cellular immune responses, which might be a key in MDS/sAML initiation and progression.